MapLight Therapeutics, Inc. Common Stock Total Assets
MapLight Therapeutics, Inc. Common Stock total assets. Based on the latest financial reports, MapLight Therapeutics, Inc. Common Stock (MPLT) holds total assets worth $368.35 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see MPLT company net worth for the company's overall valuation and market capitalisation.
Total Assets of MapLight Therapeutics, Inc. Common Stock (2022–2025)
Total assets of MapLight Therapeutics, Inc. Common Stock from 2022 to 2025. This chart illustrates how MapLight Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See today's stock price for MapLight Therapeutics, Inc. Common Stock for real-time trading data and today's change.
MapLight Therapeutics, Inc. Common Stock - Asset Composition Analysis
MapLight Therapeutics, Inc. Common Stock Total Assets Breakdown (December 2025)
MapLight Therapeutics, Inc. Common Stock total assets breakdown as of December 2025. MapLight Therapeutics, Inc. Common Stock's total assets of $368.35 Million consist of 67.7% current assets and 32.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how MapLight Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore MPLT working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MapLight Therapeutics, Inc. Common Stock's current assets represent 67.7% of total assets in 2025, a decrease from 81.3% in 2022.
- Cash Position: Cash and equivalents constituted 9.8% of total assets in 2025, down from 70.2% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
MapLight Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of MapLight Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
MapLight Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 16.52 | 4.89 | 12.72 |
| Quick Ratio | 16.52 | 4.89 | 12.72 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $299.49 Million | $58.22 Million | $169.44 Million |
MapLight Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between MapLight Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.86 |
| Latest Market Cap to Assets Ratio | 0.62 |
| Asset Growth Rate (YoY) | 250.2% |
| Total Assets | $479.51 Million |
| Market Capitalization | $297.26 Million USD |
Valuation Analysis
Below Book Valuation: The market values MapLight Therapeutics, Inc. Common Stock's assets below their book value (0.62x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: MapLight Therapeutics, Inc. Common Stock's assets grew by 250.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for MapLight Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual total assets of MapLight Therapeutics, Inc. Common Stock from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $479.51 Million | +250.22% |
| 2024-12-31 | $136.92 Million | +49.78% |
| 2023-12-31 | $91.41 Million | +132.07% |
| 2022-12-31 | $39.39 Million | -- |
About MapLight Therapeutics, Inc. Common Stock
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irrit… Read more